Edition:
United States

AstraZeneca PLC (AZN.L)

AZN.L on London Stock Exchange

4,980.50GBp
24 Nov 2017
Change (% chg)

-19.00 (-0.38%)
Prev Close
4,999.50
Open
4,991.00
Day's High
5,001.00
Day's Low
4,957.50
Volume
348,357
Avg. Vol
2,598,202
52-wk High
5,585.07
52-wk Low
3,996.00

Chart for

About

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in... (more)

Overall

Beta: 1.04
Market Cap(Mil.): £63,371.22
Shares Outstanding(Mil.): 1,265.95
Dividend: 68.90
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.51 15.54
EPS (TTM): -- -- --
ROI: -- 15.16 11.80
ROE: -- 16.57 15.75

Roche win boosts case for adding chemo to cancer immunotherapy

LONDON Cancer doctors struggling to work out the best way to use modern immunotherapy drugs now have further evidence of the benefits of adding them to chemotherapy, despite earlier scepticism.

Nov 20 2017

Spanish stocks - Factors to watch on Friday

The following Spanish stocks may be affected by newspaper reports and other factors on Friday. Reuters has not verified the newspaper reports, and cannot vouch for their accuracy:

Nov 17 2017

BRIEF-Almirall announces achievement of $80 mln sales-related milestones from agreement with Astrazeneca‍​

* ANNOUNCES ACHIEVEMENT OF $80 MILLION SALES-RELATED MILESTONES FROM AGREEMENT WITH ASTRAZENECA‍​ Source text for Eikon:

Nov 17 2017

AstraZeneca ticks another box as U.S. approves severe asthma drug

(This version of the Nov.15 story corrects the spelling of the drug in paragraphs 8, 9)

Nov 16 2017

REFILE-UPDATE 1-AstraZeneca ticks another box as U.S. approves severe asthma drug

LONDON, Nov 15 AstraZeneca has achieved another milestone in rebuilding its drug portfolio with U.S. approval of a drug for severe asthma as the company battles to put patent losses on older medicines behind it.

Nov 16 2017

BRIEF-AstraZeneca pricing new severe asthma drug Fasenra below rivals

* Says pricing Fasenra below the treatment cost of all other biologics in severe asthma

Nov 15 2017

BRIEF-Astrazeneca says U.S. FDA approved fasenra (benralizumab) for severe eosinophilic asthma

* Astrazeneca - co, Medimmune, announced that U.S. FDA approved fasenra (benralizumab) for severe eosinophilic asthma

Nov 14 2017

U.S. FDA approves AstraZeneca's asthma drug

Nov 14 Anglo-Swedish pharmaceutical firm AstraZeneca Plc on Tuesday said the U.S. Food and Drug Administration approved its drug benralizumab, as an add-on treatment for patients with severe asthma aged 12 years and older.

Nov 14 2017

BRIEF-Astrazeneca says EU approves new indication for Faslodex in combination with palbociclib

* FASLODEX (FULVESTRANT) RECEIVES EU APPROVAL FOR THE TREATMENT OF HORMONE RECEPTOR-POSITIVE ADVANCED BREAST CANCER IN COMBINATION WITH PALBOCICLIB1 Source text for Eikon: Further company coverage:

Nov 14 2017

Pfizer creates chief operating officer role for Bourla

NEW YORK Drugmaker Pfizer Inc has promoted Albert Bourla to the newly created post of chief operating officer, freeing up Chief Executive Officer Ian Read to focus more on long-term strategy and engaging with government and industry leaders.

Nov 13 2017

Earnings vs. Estimates